Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
Rhea-AI Summary
Alterity Therapeutics (NASDAQ: ATHE) announced a Late-Breaker oral presentation at the American Academy of Neurology Annual Meeting on April 21, 2026, highlighting positive clinical signals for ATH434 in Multiple System Atrophy (MSA) using the MuSyCA composite scale.
The company reported clinically meaningful efficacy in a randomized Phase 2 trial, positive open-label data in advanced MSA, and said it is preparing to initiate a Phase 3 pivotal trial.
Positive
- Late-breaker AAN presentation on April 21, 2026
- Randomized Phase 2 showed clinically meaningful efficacy for ATH434
- Preparing Phase 3 pivotal trial in MSA
Negative
- Phase 3 not yet initiated, leaving pivotal efficacy unconfirmed
- Open‑label data in advanced MSA lack randomized control
News Market Reaction – ATHE
In the Apr 16 session, ATHE gained 6.43%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.6% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 4.6x the daily average, suggesting strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | FDA feedback Phase 3 | Positive | +13.0% | Positive FDA Type C feedback supporting ATH434 Phase 3 program in MSA. |
| Mar 09 | Conference participation | Positive | +3.5% | CEO participation in Bell Potter summit and investor meetings in Australia. |
| Mar 04 | Leadership appointment | Positive | +0.0% | Appointment of Dr. Claassen as Chief Medical Advisor to advance ATH434. |
| Mar 02 | Awareness campaign | Positive | +0.3% | MSA Awareness Month outreach highlighting ATH434 Phase 2 benefits and safety. |
| Jan 30 | Cash flow update | Neutral | -2.8% | Quarterly cash flow and corporate update with Phase 2 data and Fast Track status. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, particularly around ATH434’s clinical and regulatory progress, has generally coincided with positive or stable price reactions, showing a pattern of aligned moves on updates.
Over the last few months, Alterity has consistently advanced ATH434 in Multiple System Atrophy. On Mar 30, 2026, positive FDA Type C feedback on the planned Phase 3 program saw shares gain 12.97%. Earlier in March, management visibility at a healthcare summit and the appointment of Dr. Daniel Claassen as Chief Medical Advisor supported the Phase 3 path. Awareness efforts for MSA and a Q2 FY26 cash position of A$49.2 million underpinned ongoing development. Today’s AAN late-breaker oral presentation fits into this steady progression of clinical and scientific visibility for ATH434.
Key Terms
phase 3 medical
phase 2 medical
randomized, double-blind, placebo-controlled medical
open label medical
composite scale medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and SAN FRANCISCO, April 16, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel Claassen, M.D., M.S., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will deliver an oral presentation during a Late Breaking Session at the American Academy of Neurology (AAN) Annual Meeting taking place April 18-22, 2026 in Chicago, IL, USA.
| Session: | Late-breaking Science 2 |
| Type: | Oral Presentation |
| Title: | ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale |
| Date/Time: | Tuesday, April 21, 2026, 6:21 PM CT |
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.
Authorisation & Additional information
This announcement was authorized by the Board of Alterity Therapeutics Limited.
Contacts:
Investors:
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
